Karo Bio AB Announces Extension of Existing Collaboration With Pfizer Inc. to Discover and Develop Drugs for Autoimmune Diseases

Published: Jun 26, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio AB (publ) (STO:KARO) announced today the extension of its existing research collaboration with Pfizer Inc. on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs. The collaboration that started in December 2011, aims to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases. Pfizer is responsible for all research costs of the project. Karo Bio is eligible to receive over $200 million in milestone payments in addition to any royalty fees.

Help employers find you! Check out all the jobs and post your resume.

Back to news